Immunosuppressive Acidic Protein and CA 125 Levels in Patients with Ovarian Cancer

Abstract

The serum levels of immunosuppressive acid protein (IAP) and CA 125 were determined in 98 patients with ovarian cancer, in 20 patients with benign ovarian tumors and in a group of normal postmenopausal women as controls. On the basis of the mean values of normal controls (346.46 ± 133.26 μg/ml), the IAP threshold was fixed at 613 ∣ig/ml. Increased IAP levels were found in 70.4% of patients with ovarian cancer, in 25% of benign tumors and in 4.5% of normal women. Elevated levels of CA 125 were observed in 66.6% of cancers, in 40% of benign tumors and in 6.9% of controls. In particular, in early stage ovarian cancer the combined assay of the two markers increased by about 30% with respect to CA 125 alone. The simultaneous determination of IAP and CA 125 allowed an overall sensitivity of 84% without any significant reduction of specificity.

Multiple Biomarker Panels For Early Detection of Ovarian Cancer

“…Similarly, the combination of either serum interleukin (IL)-6 [37], CASA [38,39], M-CSF [40][41][42], immunosuppressive acidic protein [43,44], prostasin [36], inhibin [45,46], soluble epidermal growth factor receptor [47] or soluble intercellular adhesion molecule-1 [6,48] with serum CA-125 values increases the overall sensitivity of CA-125 in ovarian cancer patients. Likewise, soluble mesothelin-related protein may complement CA-125 [49].…”

“…Luminex technology demonstrated that combining information on several markers using flexible statistical methods results in improved sensitivity while maintaining specificity and could ultimately lower the number of invasive procedures required for ovarian and other cancer cases detected to evaluate false-positive screening results. [17] CA-125, OVX1, M-CSF, LASA, CA-15-3, CA-72-4, CA1-9-9, CA-54/61 CART 94.3 90.9 [17] CA-125 II, CA-72-4, CA-15-3, LASA ANN 79.0 87.5 [18] CA-125, CA-72-4 95 95 [31] CA-125, TPS 81 82 [32] CA-125, CASA 88 85 [32] CA-125, CA-72-4, CA-15-3 66.7 93.1 [22] CA-125II, CA 72-4, M-CSF MDA 70 98 [33] CA-125, prostasin 92 94 [36] CA-125, CA-19-9, CEA 70 98 [67] CA-125, IAP 84 [43] CA-125, inhibin 83.9 100 [45] CA-125, IL-6, IL-8, VEGF, EGF CART 84 95 [63] Tetranectin, CA-125, CASA COX 61.7 100 [68] Leptin, prolactin, osteopontin, insulin-like growth factor-II 95 95 [62] CA-125, TATI 91 65 [69] CA-125, UGP 86 89 [70] CA 125, Inhibin 95 95 [46] CA-125, apolipoprotein A1, truncated form of transthyretin, cleavage fragment of inter-α-trypsin inhibitor heavy chain H4 74 97 [20] ANN Multiple biomarker panels for early detection of ovarian cancer -REVIEW…”

Lipoprotein(a) and CA125 levels in the plasma of patients with benign and malignant ovarian disease

“…Numerous investigations have shown that CA 125 levels on their own cannot confirm a diagnosis of cancer. Multimodal approaches combining CA125 levels with ultrasonography and vaginal examinations (Jacobs et al, 1988a) or other tumour markers (Castelli et al, 1991) are currently under investigation.…”

The Role of Circulating Antigen and Autoantibody in Diagnosing Ovarian Cancer

“…Cancer Serum levels of CA 19-9 (monosialoganglioside antigen widely used in gastrointestinal adenocarcinoma diagnostics) are elevated in 68% to 83% of mucinous ovarian cancers but in only 28% to 29% of non-mucinous types, whereas CA-125 is elevated in 80% of non-mucinous ovarian tumors [11][12][13][14] providing a differential diagnostic tool for non-mucinous versus mucinous subtypes. Other markers, alone or in combination, have also been used; serum CA 15-3, CA 72-4, and CEA levels are elevated, respectively, in 50% to 56%, 63% to 71%, and 25% to 50% of patients with ovarian cancer [15][16][17][18][19][20][21]. Additionally, these markers did not offer additional clinical benefit for monitoring ovarian cancer, suggesting that the serial measurement of these markers may play a role only in the management of patients with a normal CA 125 assay [21].…”